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ABSTRACT 
 
Fetal abnormalities are congenital abnormalities that are identified prenatally, which may 
be structural or functional in nature.  Genetic counselling is a non-directive and non-
judgmental process of information-giving, at the same time as providing psychosocial 
support.  It is offered to women and their partners who have a fetal abnormality detected 
during pregnancy.  When a fetal abnormality is detected, the patient can sometimes be 
offered a termination of pregnancy, and the decision of whether or not to continue the 
pregnancy is made by the patient.   
 
The first aim of this research was to conduct an audit of the genetic counselling service 
provided by the Division of Human Genetics, NHLS and WITS, in order to assess the 
level of service being offered to patients with diagnosed fetal abnormalities.  The second 
aim of the research was to determine what factors, if any, influenced the decision 
patients made regarding whether to continue or interrupt their pregnancy.   
 
One hundred and seventy one files of women, who received genetic counselling for an 
identified fetal abnormality during pregnancy from the division between 2002 and 2006, 
were included in the retrospective clinical audit.   
 
The patients seen for genetic counselling represent 1.1 % of the estimated number of 
women in Johannesburg who could have had abnormalities detected prenatally, based 
on the prevalence of congenital disorders in the area and an ultrasound prenatal 
detection rate of 56.2 %.  Two thirds of patients who were offered TOP chose to 
terminate their pregnancy.  The most clinically significant predictor of the decision to 
terminate an affected pregnancy was found to be an earlier gestation at offer of TOP, 
which suggests that earlier detection and diagnosis of abnormalities is beneficial to 
patients.  Overall, 62 % of patients were not offered genetic counselling follow-up 
appointments after conclusion of their pregnancy.  The genetic counselling service 
offered to patients thus needs to be improved, in particular, the follow-up service patients 
receive after TOP or delivery is not adequate.         
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CHAPTER 1 INTRODUCTION 
1.1 Introduction 
 
During the past three decades significant advancements have been made in the 
detection of fetal abnormalities.  This has been made possible by fetal 
ultrasonography and medical genetic testing of fetal cells, obtained through 
invasive procedures (Chitty, Hunt, Moore et al., 1991; Grandjean, Larroque, Levi 
et al., 1999).    
 
Women and their partners face emotionally difficult decisions including whether 
to interrupt or continue a pregnancy after the detection of fetal abnormalities 
(Drugan, Greb, Johnson et al., 1990).  Genetic counselling should be offered to 
these women and their partners after the diagnosis of a fetal abnormality to 
provide information and psychosocial support to assist in possible decision 
making.   
 
The aim of this project was firstly to audit the genetic counselling service 
provided by the Division of Human Genetics, National Health Laboratory Service 
(NHLS) and the University of the Witwatersrand (WITS) to women and their 
partners who have diagnosed fetal abnormalities.  Secondly, we aimed to assess 
which factors may be associated with the decision patients make regarding 
terminating or continuing the pregnancy.  
 
1.2 Types of fetal abnormalities 
 
Congenital disorders (also termed birth defects) are abnormalities of structure or 
function, which are present at birth (Christianson, Howson and Modell, 2006).  
Fetal abnormalities are those congenital disorders that are detected prenatally.  
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They may also be either structural or functional in nature (Sanders, Blackman, 
Hogge et al., 2002).      
 
Structural fetal abnormalities are those that affect the anatomy and morphology 
of the fetus, and often have an impact on function as a result.  Structural 
abnormalities can affect single or multiple organs, limbs, or systems (Clayton-
Smith and Donnai, 2002; Turnpenny and Ellard, 2005).  Examples of structural 
fetal abnormalities include neural tube defects (NTDs), cardiac defects such as 
ventricular septal defect (VSD), renal agenesis, diaphragmatic hernia, 
omphalocoele, cleft lip and palate and skeletal abnormalities (Sanders et al., 
2002).  Structural fetal abnormalities can often be identified during diagnostic  
fetal ultrasound examination (Green and Statham, 1996). 
 
Functional fetal abnormalities are disorders of the physiology or biochemistry of 
the fetus and are not usually associated with structural change.  These 
abnormalities can sometimes be diagnosed prenatally by analysis of fetal cells 
obtained by invasive methods.  Functional fetal abnormalities can include those 
conditions that may only have a clinical onset in later life.  Examples of functional 
fetal abnormalities include cystic fibrosis (although this can be suggested by a 
finding of meconium ileus on ultrasound examination), Huntington disease and 
certain metabolic conditions (Turnpenny and Ellard, 2005).       
 
1.3 Prevalence of fetal abnormalities 
 
Congenital disorders, that can cause death and disability, affect approximately 
seven percent of babies born worldwide every year (Christianson et al., 2006).  
However, only a small percentage of congenital disorders can be detected 
prenatally.  In South Africa, as in most of the world, many women do not have 
access to prenatal diagnosis and screening programs and therefore very few 
congenital disorders are detected before birth (Christianson et al., 2006).     
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No comprehensive data about the prevalence of detectable fetal abnormalities is 
available.  The prevalence of congenital disorders can be used to estimate the 
prevalence of fetal abnormalities, but not all congenital disorders are expected to 
be detected prenatally.  Grandjean et al. (1999) reported a prenatal detection rate 
of 56.2 % for congenital anomalies through ultrasound screening.  
 
The number of live births recorded in the Johannesburg area in 2005 was 121 
881 (StatsSA, 2006) and Christianson et al. (2006) reported a prevalence of 53.4 
congenital disorders per 1 000 live births in South Africa.  By calculation, the 
number of babies born with serious genetic congenital disorders born in the 
Johannesburg area in 2005 was approximately 6 508.  Based on the report by 
Grandjean et al. (1999) 56 % (3 644 babies) of these could theoretically have 
been detected prenatally through ultrasound screening.     
 
1.4 Detection of fetal abnormalities 
 
Prenatal screening and diagnostic tests are available for the detection of fetal 
abnormalities.  Screening tests allow groups of individuals at higher risk of having 
a baby with a specific congenital disorder to be identified.  They can then be 
offered prenatal diagnostic testing, to confirm the diagnosis (Wald and Leck, 
2000). 
 
1.4.1 Screening tests for fetal abnormalities 
 
A screening test involves the methodical application of a test or inquiry, to identify 
individuals at increased risk of a specific disorder or in this case pregnant women 
at risk of fetal abnormalities, who have not previously sought medical attention for 
that disorder.  This allows those individuals at increased risk to benefit from 
further investigation or direct preventative action (Wald and Leck, 2000).  
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Screening tests may involve simple inquiries or special tests that separate higher 
risk patients from the general population.  In a prenatal setting, inquiries may 
involve asking specific questions about maternal age, or asking general 
questions about the family history.  Patients who could be identified through 
inquiry as being at a higher risk for fetal abnormalities include women older than 
35 years (numerical chromosome abnormalities) and those with a positive family 
history of an inherited condition (Harper, 2004).  
 
Tests available for screening include fetal ultrasound, maternal serum screening 
and molecular analysis to identify carriers of common autosomal recessive 
conditions. 
 
Ultrasound is used in pregnancy as a screening tool, as well as a diagnostic tool 
for structural abnormalities.  For screening purposes, ultrasound can be used to 
measure the nuchal translucency (NT) thickness between 11 and 13 weeks 6 
days gestation.  If NT is increased the risk for Down’s syndrome, cardiac 
abnormalities, skeletal abnormalities and several other abnormalities is 
increased.  Between 18 and 23 weeks ultrasound can be used to identify soft 
markers.  Soft markers are signs identified on ultrasound that independently do 
not represent a problem, but which indicate an increased risk of a congenital 
disorder or chromosome abnormality (Green and Statham, 1996; Wald, Kennard, 
Donnenfeld et al., 2000; Papp and Fekete, 2003; Harper, 2004). 
 
Maternal serum screening can be carried out in both the first and second 
trimester.  It involves measuring the levels of various proteins in the blood of 
pregnant women and comparing them to reference levels.  A positive maternal 
serum screen can indicate an increased fetal risk for Down syndrome, Trisomy 
18, Trisomy 13 or open neural tube defects (Cunniff and the Committee on 
Genetics, 2004).        
 
Other maternal serum screening tests that are routinely performed in South 
Africa include screening for Rhesus incompatibility and syphilis infection.  
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Women who are found to be seropositive for syphilis are treated with penicillin, 
which prevents congenital syphilis.  Women who are Rhesus-negative are given 
anti-D injections to prevent maternal sensitization (Letsky, Leck and Bowman, 
2000; Peckham and Newell, 2000).   
 
When a patient is identified through screening as being at increased risk of 
having a baby with a congenital disorder, she may be offered prenatal diagnosis 
in order to obtain more information about the pregnancy (Harper, 2004). 
 
1.4.2 Diagnostic tests for fetal abnormalities 
 
Prenatal diagnostic tests provide a diagnosis, as opposed to modifying the risk 
that a congenital disorder is present, as screening tests do.  Diagnostic tests 
should be offered to high-risk patients, identified through screening, where the 
financial and psychological costs of further testing are believed to be warranted 
(Green and Statham, 1996; Wald and Leck, 2000; Harper, 2004).   
 
Prenatal diagnostic tests can be invasive or non-invasive.  Non-invasive tests 
include ultrasound and magnetic resonance imaging (MRI).  Invasive tests, such 
as chorionic villus sampling (CVS), amniocentesis, cordocentesis and fetoscopy 
can be used to obtain a sample of fetal tissue.  Once a sample of fetal tissue and 
/ or amniotic fluid has been collected a number of diagnostic tests can be 
performed.  These include routine chromosome analysis, quantitative fluorescent 
PCR, molecular analysis, enzyme assays, and biochemical tests such as 
measuring alpha-feto protein and acetylcholinesterase levels, although these 
biochemical tests are not performed routinely in the state hospitals in Gauteng 
(Turnpenny and Ellard, 2005).       
 
Some structural fetal abnormalities identified by ultrasound examination can be 
diagnostic of a specific disorder.  In these cases ultrasound is a diagnostic tool 
(Green and Statham, 1996).  In the past decade fetal MRI has become a useful 
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tool for the evaluation of fetal abnormalities, allowing detailed evaluation of the 
fetal anatomy, particularly the central nervous system (CNS), thorax, abdomen 
and placenta (Laifer-Narin, Budorick, Simpson et al., 2007).  However, it is not 
widely available for fetal prenatal diagnosis in South Africa.      
 
CVS is carried out during the first trimester, 11 – 13 weeks 6 days gestation, 
under ultrasound guidance either trans-cervically, or, more often, trans-
abdominally.  A sample of the chorionic villi is obtained, which can be analysed 
directly (when performing molecular genetic, FISH, or PCR analysis) or after cell 
culture (when performing routine chromosome analysis).  The advantage of CVS 
is that it allows diagnosis in the first trimester, although it carries a miscarriage 
risk of 1 – 2 %, and is more technically difficult than amniocentesis (Green and 
Statham, 1996; Turnpenny and Ellard, 2005).   
 
Amniocentesis, normally carried out between 16 and 20 weeks gestation, 
involves obtaining a sample of amniotic fluid from the uterus, trans-abdominally, 
under ultrasound guidance (Harper, 2004; Turnpenny and Ellard, 2005).  The 
fetal cells obtained through amniocentesis have to be cultured before routine 
chromosome analysis can take place, and therefore results normally take 3 to 4 
weeks.  For molecular genetic analysis, PCR and FISH analysis the cells do not 
need to be cultured (Green and Statham, 1996).  Amniotic fluid can also be used 
to perform enzyme assays and biochemical tests.  The disadvantage of 
amniocentesis is that the results are available fairly late in pregnancy, although 
the miscarriage risk, of 0.5 - 1 %, is lower than that for CVS (Turnpenny and 
Ellard, 2005).       
 
Cordocentesis is a procedure used to obtain a sample of fetal blood from the 
umbilical cord vessels, using ultrasound guidance.  The blood can then be used 
to diagnose specific congenital disorders (Turnpenny and Ellard, 2005).  
Cordocentesis is carried out after 20 weeks, and is associated with a 2 to 3 % 
miscarriage risk (Cunniff and the Committee on Genetics, 2004).  
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Fetoscopy is a technique, not available in South Africa, used to obtain fetal blood 
or tissue samples, which may be needed for diagnostic analysis in rare disorders, 
such as epidermolysis bullosa.  It is performed between 18 and 20 weeks 
gestation, using ultrasound guidance, and is associated with a 3 - 5 % 
miscarriage risk (Hurley and Rodeck, 2000; Turnpenny and Ellard, 2005).       
 
1.5 Outcome of pregnancies that have fetal abnormalities diagnosed 
 
When a fetal abnormality is detected during pregnancy the doctor (i.e. 
obstetrician or fetal medicine specialist) involved in the diagnosis of the fetal 
abnormality will decide whether to offer termination of pregnancy (TOP) 
depending on the gestation and the severity of the abnormality.  The decision 
about whether to have TOP is made by the woman and her partner.    
 
Part of the South African Choice on Termination of Pregnancy Act of 1996 states 
that termination of pregnancy can be carried out at any stage of pregnancy when 
two medical practitioners, or one medical practitioner and a registered midwife, 
believe that the continued pregnancy would result in a severe malformation of the 
fetus.  Severe malformation is not defined in the act, and the decision to offer 
termination of pregnancy for fetal abnormalities is left to the discretion of the 
doctors involved. 
 
The procedure used to carry out a TOP is dependent on the gestation of the 
pregnancy and the medical practitioner involved (Davies, Gledhill, McFayden et 
al., 2005).  First trimester TOP is performed by administering drugs such as 
misoprostol, to induce miscarriage.  Second trimester TOP is carried out in one of 
two ways.  The first method, dilation and evacuation, involves the dilation of the 
cervix and the surgical removal of the fetus by means of forceps.  The second 
method involves the dilation of the cervix, and then the use of prostaglandins or a 
prostaglandin-analog to induce labour.  After 24 weeks gestation, the fetus may 
be viable, and a fetocide must therefore be performed.  Fetocide involves 
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causing fetal demise prior to delivery by means of a potassium chloride injection 
into the fetal heart or umbilical cord.  Following this, labour is induced and the 
fetus is delivered (Bourguignon, Briscoe and Nemzer, 1999). 
 
1.6 Factors influencing a patient’s decision to terminate a pregnancy 
after the detection of a fetal abnormality 
 
The decision of whether to interrupt or continue a pregnancy in which fetal 
abnormalities have been identified is complex and has been shown to be 
dependent on many factors.  The acceptance rate after an offer of TOP varies 
between studies, and may differ due to the circumstances of the patients 
included in the study and the type of abnormalities detected.  Table 1-1 shows 
the rate of TOP from a number of studies. 
  
Table 1-1 Percentage of patients choosing termination of pregnancy after diagnosis of a 
fetal abnormality in 7 different research groups 
 
Fetal abnormalities detected in 
sample population 
Uptake of 
TOP (%) 
Reference 
Ultrasound detected abnormalities, 
with normal karyotypes 
 
30.2 (Pryde, Isada, Hallak et al., 1992) 
Ultrasound detected abnormalities 33.0 (Rauch, Smulian, DePrince et al., 2005) 
 
Ultrasound detected abnormalities 
 
50.5 (Stoll, Tenconi, Clementi et al., 2001) 
Perinatal lethal abnormalities 66.9 (Hassed, Miller, Pope et al., 1993) 
 
Sex chromosome abnormalities, 
diagnosed by karyotyping 
 
68.0 (Christian, Koehn, Pillay et al., 2000) 
 
Chromosome abnormalities, diagnosed 
by karyotyping 
 
75.0 (Drugan et al., 1990) 
Abnormal invasive test result, including 
chromosome abnormalities and single 
gene disorders 
 
87.8 (Zlotogora, 2002) 
Ultrasound detected abnormalities, 
abnormal invasive test results 
76.3 (Viljoen, Oosthuizen and van der 
Westhuizen, 1996) 
 
Factors that may influence the TOP decision that have been investigated include 
maternal and pregnancy factors.  Maternal factors include maternal age, 
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reproductive history, religious and cultural beliefs, as well as individual attitudes 
towards termination of pregnancy.  Pregnancy factors include the visualization of 
the abnormalities on ultrasound, the certainty of the diagnosis, the gestation of 
the pregnancy at diagnosis of the fetal abnormality,  the severity of the 
abnormality, whether the abnormality is considered lethal or not, the number of 
organ systems affected, and the particular organ systems involved (Drugan et al., 
1990; Green and Statham, 1996; Christian et al., 2000; Schechtman, Gray and 
Baty, 2002; Zlotogora, 2002; Rauch et al., 2005).  It is often difficult to separate 
these factors and the influence they have on termination of pregnancy from one 
another, as many of them are closely linked (Green and Statham, 1996).   
 
It has been shown that pregnancies with abnormalities that were either 
incompatible with life, or abnormalities that may have a severe impact on life, 
even with medical or surgical intervention, are more likely to be terminated 
(Schechtman et al., 2002; Zlotogora, 2002).  Rauch et al. (2005) also found that 
couples were more likely to opt for TOP when abnormalities in multiple organ 
systems had been detected in their pregnancy.   
 
Some studies have shown that abnormalities involving the central nervous 
system (CNS) are associated with the decision to terminate more frequently than 
abnormalities other systems (Schechtman et al., 2002; Rauch et al., 2005).  The 
certainty of the diagnosis and prognosis has also been shown to influence the 
decision to interrupt or continue an affected pregnancy.  Pryde et al. (1992) found 
that when a fetal abnormality had been diagnosed by ultrasound, and the 
prognosis was uncertain, parents tended to continue the pregnancy.   
 
Christian et al. (2000) and Drugan et al. (1990) reported that couples with 
diagnosed chromosome abnormalities, who had visualized the fetal abnormalities 
on ultrasound were more likely to terminate than couples who had not.  It is 
believed that this is because visualizing the abnormality, rather than a verbal 
explanation of diagnostic test results (e.g. karyotype or molecular results), makes 
it easier for parents to comprehend the abnormality.   
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Diagnosis early in gestation has been shown by some researchers to result in a 
decision to terminate, presumably because emotional bonding has not occurred 
to the same degree as at a later gestation (Zlotogora, 2002; Rauch et al., 2005).  
However, contrary to this studies by Drugan et al. (1990) and Pryde et al. (1992) 
found that the gestational age at diagnosis did not influence decision-making 
about TOP in patients with diagnosed fetal abnormalities. 
 
Older couples have been shown to be more likely to interrupt an abnormal 
pregnancy than younger couples when serious anomalies are present, 
suggesting an influence of maternal age on decision-making (Schechtman et al., 
2002).  In contrast, Holmes-Siedle et al. (1986) reported that older couples were 
more likely to continue pregnancies with sex chromosome abnormalities, possibly 
because they had less chance of replacing the pregnancy with a subsequent 
normal pregnancy.   
 
In South Africa 29 – 30 % of women attending antenatal clinics in Johannesburg 
are HIV positive (Mseleku, Smith and Guidozzi, 2005).  It is possible that a 
woman’s HIV status may have some impact on her decision regarding 
termination of pregnancy for a fetal abnormality, although there is no data 
available to support this hypothesis.   
 
1.7 Genetic counselling 
 
Genetic counselling is a process which aims to help people understand and 
adjust to the medical, psychological and familial implications of genetic conditions 
(Resta, Bowles Biesecker, Bennett et al., 2006).   
 
Genetic counselling aims to assist people in understanding and adjusting to the 
medical, emotional, and familial repercussions of a genetic condition.  It is a 
process that involves conversation and communication between the patient and 
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the genetic counsellor (Evans, 2006).  It incorporates taking and interpreting 
family and medical histories to determine the risk of developing or passing on a 
genetic condition.  Genetic counselling can provide information regarding the 
inheritance, testing, care, prevention and medical and community resources for a 
specific condition.  Genetic counselling also aims to provide psychosocial support 
around decision-making, by acknowledging the patient’s ability to make decisions 
and by discussing available options (Weil, 2000; Harper, 2004; Resta et al., 
2006). 
 
Genetic counselling is intended to be a non-judgmental, non-directive and 
supportive process.  Non-directive counselling means that the genetic counsellor 
does not recommend or advise any particular choice to the patient, but instead 
provides information that allows the patient to make an informed decision  
(Harper, 2004). 
 
1.7.1 Genetic counselling for fetal abnormalities 
 
The role of the genetic counsellor when counselling parents who have a fetal 
abnormality detected in pregnancy is to provide information and psychosocial 
support, including support during decision-making.  The counsellor provides the 
parents with comprehensive information regarding the detected fetal abnormality, 
the prognosis and risks for the fetus and what options are available regarding 
further testing, termination of pregnancy or care of the baby after birth.  The 
provision of this information, at the parent’s level of understanding, allows them 
to make an autonomous, informed decision regarding the pregnancy, that is in 
keeping with their ethical, social, and cultural beliefs (Weil, 2000; Harper, 2004). 
 
The diagnosis of a fetal abnormality results in a variety of emotional reactions in 
the parent, including shock, grief, guilt, and worry (Sanders et al., 2002).  The 
counsellor provides psychosocial support, by exploring the emotional and social 
consequences of a diagnosed fetal abnormality, in terms of its effects on the 
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couple, as individuals and as a partnership, their family and community.  It may 
also include exploring the parent’s feelings around the different options available 
to them, in order to assist with decision-making.  This is often achieved through 
the use of anticipatory guidance, which involves exploring with the parents the 
implications of the possible outcomes.  Reassuring parents that their reaction is 
normal in a genetic counselling session can help the parents to accept the way 
they are feeling (Weil, 2000).     
   
Once the parents have made an informed decision regarding further testing (e.g. 
amniocentesis) or the outcome of the pregnancy (e.g. termination of pregnancy), 
it is the responsibility of the genetic counsellor to continue to support them and to 
help facilitate their choice.   The counsellor assists the parents in obtaining 
further testing or termination of the pregnancy by referring the parents to the 
appropriate professionals.  A follow-up appointment for the parents is made for 
an appropriate period after the initial session.  This interval is dependent on the 
parent’s needs, the gestational age of their pregnancy and on what action they 
have decided on.  Follow-up appointments can be purely supportive in nature, or 
they may include result giving.  Results could be either the invasive test results or 
the results of the examination of the fetus after termination, including post-
mortem and X-ray results.  If the parents have continued the pregnancy, the 
genetic counsellor can assist with planning the delivery and arranging for early 
intervention.  The follow-up appointment after delivery will possibly involve an 
examination of the baby and referral of the baby for any necessary interventions, 
as well as the provision of psychosocial support (Weil, 2000). 
 
1.7.2 Dealing with the emotional impact of terminating an affected pregnancy in 
genetic counselling 
 
Parents who choose to terminate affected pregnancies often experience feelings 
of shock, denial and acute guilt (Dallaire, Lortie, Des Rochers et al., 1995; Fonda 
Allen and Mulhauser, 1995; Suslak, Scherer and Rodriguez, 1995).     
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Parents experience grief and mourning for the lost healthy fetus.  They may feel 
that they have “abandoned the fetus” or “killed the baby” by interrupting the 
pregnancy, and feel guilty as a result of this belief.  In order for them to reach a 
state of acceptance they will go through the typical grief responses, including 
anger, denial, guilt, depression, and bargaining (Dallaire et al., 1995; Fonda Allen 
and Mulhauser, 1995; Suslak et al., 1995; Weil, 2000).  The role of the genetic 
counsellor in this situation involves a continuation of empathic, non-judgmental 
counselling and supporting the parents through the grieving process (Weil, 2000). 
 
The genetic counsellor can also assess the parents’ reaction to the TOP, and 
refer the parents to appropriate specialists when necessary.  This may include 
referrals to psychologists and grief counsellors.    
 
1.7.3 Dealing with the emotional impact of continuing an affected pregnancy in 
genetic counselling 
 
When parents choose to continue an affected pregnancy they may experience 
grief regarding the loss of a normal, wanted child.  This experience of grief and 
mourning may be much the same as the grief process experienced by parents 
who lose pregnancies or choose to terminate.  The parents may feel uncertain as 
to what the future holds, leaving them feeling fearful, anxious and overwhelmed 
(Fonda Allen and Mulhauser, 1995).  It is important that the genetic counsellor 
provides empathy, emotional support, normalization of the parents’ feelings, and 
assists the parents to identify their individual and social support systems (Weil, 
2000).     
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1.8 Genetic counselling clinics 
 
The Division of Human Genetics, NHLS and WITS, runs Genetic Counselling 
Clinics at Chris Hani Baragwanath Hospital, Johannesburg Hospital, Coronation 
Hospital and Donald Gordon Medical Centre in Johannesburg, South Africa.   
 
Pregnant patients, and if they wish, their partners, are referred for genetic 
counselling in two instances.  Firstly, patients may be referred for genetic 
counselling if they are considered to be at increased risk of having a fetus with 
fetal abnormalities through a screening test or because of a history of fetal 
abnormalities.  Secondly, patients may be referred if a fetal abnormality is 
detected by ultrasound examination or through invasive testing.  Patients are 
usually referred for genetic counselling by clinicians and nurses and are seen by 
either genetic counsellors or clinical geneticists. 
 
1.9 Purpose of this study 
 
The study to be undertaken comprised two components: i) to audit the genetic 
counselling service provided to patients with fetal abnormalities by the Division of 
Human Genetics, NHLS and WITS, and, ii) to assess the factors that may be 
associated with a patient’s decision to terminate a pregnancy after fetal 
abnormalities are detected.   
 
Auditing the genetic counselling service provided to patients will provide 
knowledge about the patients that were seen and describe the service that they 
received.  Knowledge about the service being offered to patients with fetal 
abnormalities will allow improvements in the service to be made, especially if 
short comings are identified.         
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The literature showed that some factors may be important predictors of parental 
decisions regarding termination of pregnancy for fetal abnormalities, although 
there is little consensus in the literature about which factors these are.  
Knowledge of the factors that may be associated with parental decisions 
regarding termination of pregnancy in our patient population would help the 
genetic counsellors in the unit to have greater understanding of their patients.  
This may give the counsellors more insight into their patients’ experiences and 
provide more opportunities for the counsellors to address their patients’ issues 
and to provide support to them. 
 
1.10 Study objectives 
 
The purpose of this study was, firstly to audit the service provided to patients with 
diagnosed fetal abnormalities in the Genetic Counselling Clinics.  This was done 
by determining: 
 
• How many patients were seen for genetic counselling for fetal 
abnormalities at the NHLS / WITS Genetic Counselling Clinics relative to 
the estimated number of congenital disorders that occurred in the 
Johannesburg area 
• The demographics of the patients seen including age, ethnicity, 
employment status, and relationship status 
• How many patients received follow-up appointments, including both 
patients choosing termination of pregnancy and those continuing the 
pregnancy, how many attended their follow-up appointments, and the time 
interval between the initial appointment and the follow-up appointment.  
The reason why no follow-up appointment was made, when this was the 
case, was also documented. 
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Secondly, factors that may be associated with the decision to terminate a 
pregnancy where a fetal abnormality has been identified were assessed by 
investigating: 
 
• How many patients decided to terminate the pregnancy after the diagnosis 
of a fetal abnormality 
• If patients decisions regarding termination of pregnancy were correlated 
with any of the following factors: 
 
o The circumstances of the patient (maternal age at diagnosis of the 
abnormalities, ethnicity, parity, relationship status, HIV status) 
o Gestation at diagnosis of the fetal abnormality 
o Gestation when TOP was offered 
o Whether the abnormality involved one or multiple organ systems 
o Whether there was CNS involvement or not  
o Whether diagnostic testing was performed 
o The result of the diagnostic testing 
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CHAPTER 2 METHODS 
 
This study was a retrospective clinical audit of the genetic counselling records at 
the Division of Human Genetics, NHLS and WITS, in Johannesburg, South 
Africa.  The research project was approved unconditionally by the Human 
Research Ethics Committee (Medical) (Protocol number M060944) (Appendix A). 
 
2.1 Study population 
 
The study population included all pregnant women who received genetic 
counselling for an identified fetal abnormality during pregnancy, at a clinic run by 
the Division of Human Genetics, NHLS and WITS.  A fetal abnormality in this 
study was defined as a congenital disorder that was detected prenatally and was 
either structural or functional in nature.   
 
2.2 Study sample 
 
Consecutive sampling was used to select the study sample.  The sample 
included pregnant women who received genetic counselling for an identified fetal 
abnormality during pregnancy, at a clinic run by the Division of Human Genetics, 
NHLS and WITS, between January 2002 and December 2006.  The clinics were 
run at Chris Hani Baragwanath Hospital, Coronation Hospital, Johannesburg 
Hospital or Donald Gordon Medical Centre.  Most patients were seen by a 
genetic counsellor, although some were seen by clinical geneticists.  Patients 
had been referred to the clinic, either when they had a family history of a genetic 
condition, when they were screen positive or when a fetal abnormality had been 
identified on ultrasound examination.  Patients were only included in the study 
when a fetal abnormality had been identified on ultrasound or invasive testing. 
Patients who had a family history or who were screen positive were excluded 
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from the study when ultrasound examination or invasive testing did not reveal the 
presence of a fetal abnormality in the current pregnancy.  Patients were also 
excluded from the study if they had had more than one pregnancy in which fetal 
abnormalities had been diagnosed.   
 
2.3 Data collection 
 
A genetic counselling file is made for every patient seen at the Genetic 
Counselling Clinics.  These files include demographic information, a family 
history pedigree, notes made by the counsellor regarding the counselling session 
and a copy of a detailed report written to the referring doctor or the patient.  The 
demographic information includes details about the patient and their partner 
including their names, dates of birth, employment details, contact details, hospital 
number or medical aid details, the referring doctors name, and the diagnosis (see 
Appendix B for an example of the information sheet).  The family history is taken 
in the form of a three generation pedigree, and includes information about 
medical and social problems in the family.  The counsellor makes notes about 
each session in the file, including information about what was discussed during 
the session, what options were discussed and offered, what decisions were 
made by the patient and psychosocial issues that arose.   
 
After a patient has been seen for genetic counselling, their file is registered in the 
department and their name and the date of the session are written onto manual 
filing cards.  These cards are specific for each diagnosis and include cards for 
fetal abnormalities, positive screening tests and other specific abnormalities.  In 
addition, a Microsoft Access database of the patients seen for genetic 
counselling has been kept since 2002, which records the name of the patient, the 
date of the session and the diagnosis.  Patients were identified from this 
database by searching for the relevant diagnosis, for example, fetal 
abnormalities.  The Cytogenetic and Molecular Laboratories keep databases that 
record the results of all the prenatal tests performed.  These databases record 
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the name of the patient, the result and the year the test was performed.  These 
records were used to identify other patients who may have received genetic 
counselling for fetal abnormalities, but that were missed using the filing system 
and other databases.  The relevant patient counselling files were obtained from 
the storage and filing facilities within the Division of Human Genetics, NHLS and 
WITS.      
 
Each file was randomly allocated a subject code, which was typed into a master 
list with the patient’s name.  Only the researcher and her supervisors had access 
to the master list.  
 
Information was then collected from the included files, and written onto the data 
collection sheet (Appendix C), along with the subject code that was recorded in 
the master list.  To ensure anonymity, the data collection sheets did not contain 
patient names.  Patients were identified by their subject code throughout the 
study. 
 
Once information from each file had been entered onto a data collection sheet a 
database of the files which met the research criteria, as described in Section 2.1, 
was created using Microsoft Excel.  Categorical information was coded in the 
database so that each variable had several options that were represented as 
numbers.  The following information was entered into the database:  
 
• Information about the patients with diagnosed fetal abnormalities seen for 
genetic counselling including: 
o Maternal date of birth  
o Maternal age at diagnosis of the fetal abnormality  
o Ethnicity - This was assumed from the patient’s name and surname 
o Relationship status 
o Employment status   
o Parity  
o Number of fetuses in the pregnancy  
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o The HIV status of the patient 
• Information regarding the diagnosed fetal abnormalities including: 
o Gestational age at diagnosis  
o The fetal abnormalities identified  
o The number of organ systems affected.  This was recorded as a 
value and then categorised into single or multiple abnormalities.  
Multiple organ systems affected included abnormalities that were 
separate entities in multiple organs, as well as abnormalities where 
an abnormality in one organ system caused abnormalities in other 
organ systems.  For example, when hydrocephalus and NTDs 
occurred together it was recorded as abnormalities in multiple 
organ systems.    
o The organ system/s affected, which was further classified into 
whether there was CNS involvement, including intracranial 
abnormalities and neural tube defects, or whether there was no 
CNS involvement 
o The diagnostic procedures performed  
o The results of the diagnostic procedures 
• Information regarding the outcome of the pregnancy was also collected, 
including: 
o Whether termination of pregnancy was offered to the patient  
o The gestational age at which termination of pregnancy was offered  
o The patient’s decision regarding termination of pregnancy 
• Information collected regarding the genetic counselling service provided to 
the patients with diagnosed fetal abnormalities included: 
o The initial reason for referral to genetic counselling 
o The dates of the genetic counselling sessions 
o The hospital where the patient was counselled 
o The number of genetic counselling sessions the patient had during 
the pregnancy 
o Whether a follow-up appointment was made and, if not, the reason 
for this  
 21 
o Whether the patient attended the follow-up appointment 
o The interval between the last appointment during the pregnancy 
and the follow-up appointment after the pregnancy  
 
2.4 Data analysis 
 
Microsoft Excel, Stata Statistical Software Version 8.0 and two statistical 
websites were used to perform the statistical analysis in this research.  The 
statistical websites used were GraphPad (Motulsky, 2007) and Sisa (Uitenbroek, 
1997).  A statistician was consulted prior to the start of the project to ensure that 
the data were collected appropriately and for assistance with the analysis of the 
data.   
 
2.4.1 Microsoft Excel functions 
 
The count function in Microsoft Excel was used to determine the number of 
patients seen for genetic counselling regarding a fetal abnormality between 2002 
and 2006.  The count function was also used to determine the number of patients 
seen for genetic counselling in terms of their ethnic group, relationship status, 
employment status, parity, number of fetuses in the pregnancy, initial reason for 
referral for genetic counselling, and HIV status.   
 
The count function was also used to describe the fetal abnormalities detected, in 
terms of the number of organ systems affected, the numbers of specific organ 
system/s affected, the number of patients who had abnormalities involving the 
CNS, the number of diagnostic procedures performed, and the number of 
diagnostic procedures with abnormal results.  It was also used to describe the 
outcome of the pregnancy, in terms of how many patients were offered TOP and 
how many of those patients chose to terminate the pregnancy.   
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In addition, the count function was used to describe the genetic counselling 
service provided to patients, in terms of the number of genetic counselling 
sessions during the pregnancy, the number of patients who were given follow-up 
appointments for after TOP or delivery, and how many patients attended their 
follow-up appointment.  The count function was also used to describe the reason 
why no follow-up appointment was made for after TOP or delivery. 
 
The frequency function of Microsoft Excel was used to determine the trend in 
patient numbers over time.   
 
The average maternal age, the average gestation at diagnosis of the fetal 
abnormality, the average gestation when TOP was offered, and the interval 
between the last appointment in the pregnancy and the follow-up appointment 
were calculated by using the average and difference functions of Microsoft Excel. 
2.4.2 Proportion of patients with diagnosed fetal abnormalities who received 
genetic counselling from the Division of Human Genetics, NHLS and WITS 
 
To determine the proportion of women with diagnosed fetal abnormalities seen 
for genetic counselling by the Division of Human Genetics, NHLS and WITS, it 
was necessary to look at the number of patients seen for genetic counselling for 
fetal abnormalities relative to the estimated number of congenital disorders in the 
Johannesburg area.  This provides an over estimate of the number of fetal 
abnormalities detected, since not all congenital disorders are detected prenatally.  
In addition, the number of congenital disorders that would potentially be 
detectable prenatally was estimated. 
 
2.4.3 Comparison of patients who chose to terminate an affected pregnancy and 
those who chose to continue  
 
The Fischer’s exact test (for categorical variables) and the two sample t-test with 
equal variance (for continuous variables) were used to determine whether there 
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were any significant differences between patients who chose to TOP and those 
who chose to continue their pregnancy, in terms of: 
 
• Continuous variables -  
o Maternal age at diagnosis of the abnormality 
o Gestation at diagnosis of the abnormality 
o Gestation when TOP was offered 
• Categorical variables -  
o Ethnicity 
o Relationship status 
o Parity 
o HIV status 
o Number of organ systems found to have abnormalities in the 
fetus 
o Whether there was CNS involvement or not 
o Whether diagnostic testing was performed 
o The result of diagnostic testing 
o The number of genetic counselling sessions the patient had 
during the pregnancy 
o Whether a follow-up appointment was made for after TOP or 
delivery 
o The interval between the last appointment in the pregnancy and 
the follow-up appointment. 
 
Microsoft Excel was used to perform the two sample t-test, while two statistical 
websites, GraphPad and Sisa, were used to perform the Fischer’s exact test.  
These tests analysed the variables as independent factors, assuming no 
relationship between them.     
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2.4.4 Determination of factors that may be associated with the decision to 
terminate or continue a pregnancy after the detection of a fetal abnormality 
 
Logistic regression analysis, using Stata Version 8.0, was used to determine the 
variables that were the most likely to influence the decision patients make about 
whether to terminate or continue an affected pregnancy.  The goal of logistic 
regression is to determine the best fitting, clinically realistic model that describes 
the relationship between a dependent variable (i.e. to terminate or continue an 
affected pregnancy) and a set of independent variables (categorical and / or 
continuous variables) (Bewick, Cheek and Ball, 2005).    
 
Stepwise logistic regression is one method of entering the independent variables 
into the model, where the variables are entered sequentially and the statistical 
software (i.e. Stata Version 8.0) then excludes non-significant variables 
automatically when p ≥ 0.1.  The following variables were included in the 
stepwise logistic regression analysis, in a random order:  
 
• Continuous variables -  
o Maternal age at diagnosis of the abnormality 
o Gestation at diagnosis of the abnormality 
o Gestation when termination of pregnancy was offered  
• Categorical variables -  
o Ethnicity.  This was simplified to a comparison between Black and 
White patients.  Patients from other groups were excluded 
o Relationship status  
o Parity 
o Number of organ systems affected by the detected abnormalities 
o Whether there was CNS involvement or not 
 
These variables were included in the stepwise logistic regression because they 
have been shown in the literature to have an influence on patients’ decisions 
regarding TOP or continuation of a pregnancy after the detection of fetal 
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abnormalities.  Certain variables that we suspected may also have an influence 
on the decision regarding the outcome of the pregnancy included the patient’s 
HIV status, whether patients chose to have diagnostic testing, and the result of 
diagnostic testing.  These variables were excluded from the logistic regression 
analysis since data were not available for all the patients in the sample group.  
Including these variables would have resulted in a considerable reduction in the 
sample number. 
 
Based on the results of the stepwise logistic regression, where non-significant 
variables were automatically removed, manual logistic regression was then used 
to determine the best fitting model from the remaining variables, which included: 
 
• Continuous variables –  
o Gestation at diagnosis of the abnormality 
o Gestation when termination of pregnancy was offered 
• Categorical variables –  
o Ethnicity 
o Number of organ systems affected by the detected abnormalities. 
 
The best model needed to be one that was acceptable with the clinically 
expected results.  The model needed to fit with what made sense and could be 
explained through clinical experience, as reported in the literature.  This was 
done by running a number of different models and assessing the results, 
eventually determining which model was most acceptable.  For each independent 
variable in the model, an odds ratio with 95 % confidence interval was calculated. 
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CHAPTER 3 RESULTS 
 
3.1 Introduction 
 
The first aim of this study was to describe the patients seen for genetic 
counselling after the diagnosis of a fetal abnormality at the Division of Human 
Genetics, NHLS and WITS, and to assess the service they received.  The second 
aim was to determine which factors influenced patient choice regarding 
termination or continuation of the affected pregnancy.  A retrospective clinical 
audit of the genetic counselling files was done to achieve these aims.     
 
The results of this investigation are presented as follows: 
 
• The trend in the number of patients with diagnosed fetal abnormalities 
seen for genetic counselling by the Division of Human Genetics, NHLS 
and WITS, from 2002 to 2006 
• Description of the patients with diagnosed fetal abnormalities seen for 
genetic counselling 
• Description of the fetal abnormalities diagnosed in those patients seen for 
genetic counselling 
• Assessment of factors that may influence a woman’s choice regarding 
termination of pregnancy for diagnosed fetal abnormalities 
• The number of patients choosing termination of pregnancy for diagnosed 
fetal abnormalities after genetic counselling 
• The genetic counselling service provided to patients with diagnosed fetal 
abnormalities at the Division of Human Genetics, NHLS and WITS 
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3.2 Number of patients seen for genetic counselling regarding a 
diagnosed fetal abnormality between 2002 and 2006 
 
The number of patients seen for genetic counselling for a diagnosed fetal 
abnormality between January 2002 and December 2006 and fulfilling our 
research criteria was 171.  Figure 3-1 shows the changing number of patients 
seen each year of the study period.  
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Figure 3-1 Trend in the number of patients with diagnosed fetal abnormalities seen for 
genetic counselling at the Division of Human Genetics, NHLS and WITS, over the 
study period, January 2002 – December 2006. 
 
The estimated number of babies born with congenital disorders (excluding 
conditions caused by teratogen exposure, e.g. Fetal Alcohol Spectrum Disorder) 
in the Johannesburg area in 2005 is 6 508.  This is calculated by using the 
estimated prevalence of congenital disorders in South Africa of 53.4 per 1, 000 
live births (Christianson et al., 2006) multiplied by the total number of live births in 
the Johannesburg area in 2005 (121 881) (StatsSA, 2006).  Grandjean et al. 
(1999) estimated that 56.2 % of congenital anomalies are detectable prenatally 
through ultrasound screening.  This suggests that approximately 3 657 of the 6 
508 babies with congenital abnormalities born in 2005 could have been detected 
prenatally.  As shown in Figure 3-1, 39 patients with diagnosed fetal 
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abnormalities were seen for genetic counselling in 2005.  This represents 0.6 % 
(1 in 167) of the 6 508 individuals with congenital disorders and 1.1 % (1 in 91) of 
the individuals with congenital disorders that could have been detected prenatally 
by ultrasonography in the Johannesburg area in 2005.   
 
3.3 Patient information 
 
The average age of patients who received genetic counselling for a diagnosed 
fetal abnormality was 30 years and 7 months, with the youngest being 17 and the 
oldest 49 years old.  The majority of patients were Black (123, 72 %), in a 
relationship but not married (105, 63 %), and approximately half were known to 
be employed (90, 53 %).  The affected pregnancy was the first one for 
approximately 27 % of patients.  The HIV status of the majority of patients was 
not known, but of those 46 patients whose status was known, 26 (57 %) were 
HIV positive.  The description of the patients seen is reflected in Table 3-1.       
 
Table 3-1 Description of patients with a diagnosed fetal abnormality seen for genetic 
counselling by the Division of Human Genetics, NHLS and WITS. 
Variable Data Variable Data 
Maternal age at diagnosis (yr) 30.60 ± 7.88 Parity n % 
Age range (yr) (n = 171) 17 – 49 0 47 (27.5) 
   1 52 (30.4) 
Maternal ethnicity
a 
n % 2 38 (22.2) 
Black 123 (72.3) 3 22 (12.9) 
White 26 (15.3) 4+ 12 (7.0) 
Other  21 (12.4) Total 171 (100.0) 
Total 170 (100.0)    
   Singleton / Twin n % 
Employment status n % 1 163 (95.3) 
Employed, self-employed 90 (52.6) 2 8 (4.7) 
Unemployed 72 (42.1) Total 171 (100.0) 
Student / Scholar 9 (5.3)    
Total 171 (100.0) HIV status n % 
   Unknown 125 (73.1) 
Relationship status
a 
n % Positive 26 (15.2) 
In a relationship 105 (63.3)  Negative 20 (11.7) 
Married 54 (32.5) Total 171 (100.0) 
Single, widowed, divorced,                             
or separated 
7 (4.2)    
Total 166 (100.0)    
a Some data were missing or unclear in the files, therefore the total does not add up to 171 
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3.4 Fetal abnormalities diagnosed in the study sample 
 
The majority of patients seen for genetic counselling were initially referred 
because an abnormality had been detected on ultrasound.  However, 14 % were 
initially referred for advanced maternal age and had fetal abnormalities detected 
by ultrasound examination or invasive testing after the initial genetic counselling 
referral (Figure 3-2).   
 
Abnormalities in more than one organ system were detected on ultrasound in 102 
patients (60 %), while 48 had a single organ system affected (28 %).  No 
abnormality was seen on ultrasound in 21 patients (12 %).  In these patients the 
fetal abnormality was diagnosed by invasive testing.  There was intracranial CNS 
involvement in 60 (35 %) patients, with cardiovascular abnormalities and 
abnormalities of the neck and face comprising the next two largest proportions of 
systems with abnormalities (Figure 3-3).  The two most common intracranial CNS 
abnormalities were hydrocephalus and Dandy-Walker malformations.  In some of 
these patients the hydrocephalus was due to the Dandy-Walker malformation 
and in some patients the hydrocephalus was isolated or due to other causes.  
Cleft lip and / or palate was the most commonly detected abnormality affecting 
the neck and face, while VSD’s were the most commonly detected cardiac 
abnormality.  Approximately 44 % (75) of abnormalities were diagnosed after 24 
weeks gestation.   
 
All patients who received counselling had had ultrasound examination, and 
approximately two thirds had further diagnostic testing.  Of those 44 pregnancies 
where a diagnosis was made through invasive testing, 25 also had abnormal 
findings on ultrasound examination (56.8 %).  The most common abnormality 
diagnosed through invasive testing was Trisomy 21 (14, 32 %).  Of the 14 
pregnancies diagnosed with Trisomy 21, seven of these were considered to be at 
increased risk due to their advanced maternal age (AMA) and two of these also 
had abnormalities detected on ultrasound examination, two had positive maternal 
serum screening tests, two had been referred for family histories for other genetic 
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conditions and three had abnormalities detected on ultrasound.  A summary of 
the referral indications, organ systems affected and testing is shown in Table 3-2.    
 
Table 3-2 Description of the fetal abnormalities diagnosed from January 2002 until 
December 2006, in patients who received genetic counselling from the Division of 
Human Genetics, NHLS and WITS. 
Data Data 
Variable n % Variable n % 
Initial reason for referral for genetic 
counselling
a
  
No. of organ systems with abnormalities 
detected on U/S
f 
   Multiple 102 (59.6) 
Abnormality on U/S
f 
140 (81.9) Single 48 (28.1) 
Advanced maternal age 24 (14.0) No abnormality on U/S
 
21 (12.3) 
Family History 12 (7.0) Total 171 (100.0) 
Teratogen exposure 5 (2.9)    
Positive screening test
b 
4 (2.3) 
Diagnostic tests performed, excluding 
U/S
f 
No. of patients 171 (108.1) Amniocentesis 50 (51.5) 
   Cordocentesis 30 (30.9) 
Gestational age at diagnosis CVS 14 (14.4) 
≤ 12 weeks 10 (5.8) STORCH screen 8 (8.2) 
13-24 weeks 86 (50.3) 
No. of patients who 
had diagnostic tests 97 (105.0) 
≥ 24 weeks
g
 75 (43.9) 
Total tests 
performed
e
 102 (100.0) 
Total 171 (100.0)    
   
Patient results for diagnostic tests, 
excluding U/S
f 
   Normal 53 (54.6) 
Organ systems in which abnormalities were 
detected on U/S
c, f
  Abnormal 44 (45.4) 
CNS (Intracranial) 60 (35.1) Total 97 (100.0) 
Cardiovascular 46 (26.9)    
Neck and face 44 (25.7) Abnormal test results   
Skeletal 40 (23.4) Trisomy 21 14 (31.8) 
Genitourinary 35 (20.5) Trisomy 18 10 (22.7) 
Amniotic fluid volume 33 (19.3) Single gene disorder 6 (13.6) 
Gastrointestinal 31 (18.1) Trisomy 13 4 (9.2) 
Pulmonary
d 
26 (15.2) 
Other chromosome 
abn 3 (6.8) 
Fetal oedema 19 (11.1) Turner syndrome 3 (6.8) 
CNS (Neural tube) 10 (5.8) Triple X syndrome 2 (4.5) 
Other 9 (5.3) Klinefelter syndrome 1 (2.3) 
Growth retardation 3 (1.8) STORCH 1 (2.3) 
No. of patients
 
171 (209.9) Total 44 (100.0) 
a Some patients had more than one indication, but all had a diagnosed fetal abnormality 
b Positive screening tests include AMA, positive maternal serum tests, increased nuchal translucency and soft 
markers on ultrasound 
c More than one organ system can be affected in each pregnancy; therefore the total is greater than 100 % 
d Pulmonary abnormalities are generally secondary to other abnormalities, e.g. skeletal or genitourinary 
abnormalities 
e Some patients had more than one type of diagnostic test 
f Ultrasound 
g 24 weeks is considered the gestation of viability in South Africa 
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Figure 3-2 Initial reason for referral to Genetic Counselling Clinics, run by the Division of 
Human Genetics, NHLS and WITS, in patients who had fetal abnormalities 
diagnosed in their pregnancy.  Patients may have had more than one indication 
for referral. 
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Figure 3-3 Organ systems affected by fetal abnormalities that were detected on ultrasound, 
in patients who were seen for genetic counselling by the Division of Human 
Genetics, NHLS and WITS.  The proportion of patients with single organ systems 
affected compared to the proportion of patients with multiple organ systems 
affected is shown. 
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3.5 Comparison of patients who chose termination of pregnancy to 
those who chose to continue their pregnancy after the diagnosis 
of a fetal abnormality 
 
Univariate analysis was used to determine if any significant differences existed 
between those patients who chose to terminate their pregnancies with those who 
chose to continue their pregnancies, after the diagnosis of a fetal abnormality.   
 
As shown in Table 3-3, Black patients were more likely to continue a pregnancy 
in which fetal abnormalities had been diagnosed than patients from other ethnic 
groups (p = 0.031).  Although not significant, patients who chose to terminate 
their pregnancy after the diagnosis of a fetal abnormality were, on average 30.5 
years old compared to those who chose to continue their pregnancy, who were 
on average 33.3 years old (Table 3-3).   
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Table 3-3 Comparison of the patients who chose to terminate and those who chose to 
continue their pregnancy after the diagnosis of a fetal abnormality.  All patients 
had genetic counselling provided by the Division of Human Genetics, NHLS and 
WITS and were offered TOP. 
Variable TOP Continue p-value 
Mean maternal age (years)  
(n = 113) 
30.534 ± 7.894 33.300 ± 7.573 0.074
a
 
    
 n % n %  
Ethnicity (n = 107)      
White 18 (26.9) 4 (10.0) 
Black 45 (67.2) 29 (72.5) 
Indian, Mixed ancestry, Other 4 (6.0) 7 (17.5) 
0.031
b
* 
Total 67 (100.0) 40 (100.0)  
      
Relationship status (n = 113)     
Married, in a relationship 68 (93.2) 37 (92.5) 
Single, divorced, widowed 5 (6.8) 3 (7.5) 
1.000
b 
Total 73 (100) 40 (100.0)  
      
Parity (n = 113)      
0 20 (27.4) 10 (25.0) 
1 25 (34.2) 9 (22.5) 
2+ 28 (38.3) 21 (52.5) 
0.292
b 
Total 73 (100.0) 40 (100.0)  
      
HIV status (n = 45)      
Positive 9 (60.0) 16 (53.3) 
Negative 6 (40.0) 14 (46.7) 
0.757
b 
Total 15 (100.0) 30 (100.0)  
a 2-tailed p-value determined through two-sample t-test with equal variance 
b 2-tailed p-value determined through Fischer’s exact test 
* Statistically significant at the 5 % level 
 
Sixty nine percent (50) of the patients who chose to terminate affected 
pregnancies had abnormalities detected in multiple organ systems compared to 
55 % (22) of patients who chose to continue their pregnancy (Table 3-4).  There 
was no significant difference in the decision to TOP between patients who 
underwent diagnostic testing and had a normal result and those who had an 
abnormal result (Table 3-4).  Pregnancies found to be affected by single gene 
disorders were terminated in the majority of pregnancies (five pregnancies versus 
one).  The gestation when termination was offered was approaching significance 
as a factor influencing the decision to terminate an affected pregnancy.  This 
suggests that for every week later in the pregnancy that TOP was offered, 
patients were less likely to terminate an affected pregnancy.  The offer of TOP 
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was made at 26 weeks gestation on average when patients chose to continue the 
pregnancy.  In contrast, TOP was offered on average at 23 weeks gestation 
when patients chose to terminate the pregnancy (Table 3-4).   
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Table 3-4 Comparison of the diagnosed fetal abnormalities, including gestation at diagnosis 
and offer of termination, comparing patients who chose to terminate the affected 
pregnancy and those who chose to continue.  All patients received genetic 
counselling from the Division of Human Genetics, NHLS and WITS, and were 
offered TOP. 
Variable TOP Continue p-value 
Mean gestation at diagnosis (n = 113) (weeks) 22.603 ± 7.121 24.550 ± 6.536 0.155
a
 
    
Mean gestation at offer of TOP (n = 113) (weeks) 23.041 ± 6.957 25.625 ± 6.740 0.059
a
 
      
 n % n %  
Gestation at offer of TOP (n = 113)      
≤ 12 weeks 0 (0.0) 0 (0.0) 
13-24 weeks 40 (54.8) 16 (40.0) 
≥ 24 weeks
c
 33 (47.1) 24 (60.0) 
Total 73 (100.0) 40 (100.0) 
0.144
b 
 
Number of organ systems affected on ultrasound (n = 113) 
No abnormality on U/S 9 (12.3) 6 (15.0) 
Single 14 (19.2) 12 (30.0) 
Multiple 50 (68.5) 22 (55.0) 
Total 73 (100.0) 40 (100.0) 
0.318
b 
      
CNS vs. Non-CNS abnormality (n = 113) 
CNS   41 (56.2) 21 (52.5) 
Non-CNS 32 (43.8) 19 (47.5) 
Total 73 (100.0) 40 (100.0) 
0.843
b 
      
Whether diagnostic testing, apart from ultrasound, was performed (n = 113) 
Yes 49 (67.1) 24 (60.0) 
No 24 (32.9) 16 (40.0) 
Total 73 (100.0) 40 (100.0) 
0.538
b 
      
Diagnostic test result (n = 67)     
Abnormal 25 (51.0) 15 (62.5) 
Normal 24 (49.0) 9 (37.5) 
Total 49 (100.0) 24 (100.0) 
0.455
b 
      
Abnormal test result (n = 38)      
Trisomy 21 9 (36.0) 4 (26.7) 
 Trisomy 13 / 18 8 (32.0) 6 (40.0) 
Sex chromosome aneuploidies 3 (12.0) 2 (13.3) 
Other chromosome abnormalities 0 (0.0) 2 (13.3) 
Single gene disorder 5 (20.0) 1 (6.7) 
0.373
b
 
Total 25 (100.0) 16 (100.0)  
a 2-tailed p-value determined through two-sample t-test with equal variance 
b 2-tailed p-value determined through Fischer’s exact test  
c 24 weeks is considered the gestation of viability in South Africa 
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3.6 Factors found to have an impact on a patient’s choice regarding 
TOP for a detected fetal abnormality 
 
From all the variables that were included in the stepwise logistic regression 
analysis, the following were found to be the ones that may be involved in a 
patient’s decision to terminate or continue a pregnancy affected by a fetal 
abnormality (Table 3-5)): 
  
• the ethnicity of the patient 
• the number of organ systems affected 
• the gestational age when the fetal abnormality was diagnosed, and 
• the gestation when TOP was offered   
 
CNS involvement, parity, relationship status and maternal age were eliminated 
from the model by the Stata Version 8.0 software, as p ≥ 0.1. 
 
Table 3-5 Stepwise logistic regression results showing the factors that were considered 
influential in a patient’s decision to terminate or continue a pregnancy affected 
with a fetal abnormality (n = 113).  All patients in the sample group received 
genetic counselling from the Division of Human Genetics, NHLS and WITS.  The 
odds ratios, significance levels, and 95 % confidence intervals are shown. 
Variable Odds Ratio 95 % Confidence Interval p-value 
Single organ system affected 1.74 0.319 9.529 0.521 
Multiple organ systems affected 4.31 0.900 20.660 0.068 
White ethnic group 4.81 0.980 23.652 0.053 
Black ethnic group 0.33 0.083 1.318 0.117 
GA at TOP offer 0.69 0.496 0.960 0.027* 
GA at diagnosis of abnormality 1.39 0.998 1.947 0.052 
   
Further modeling of the variables determined by the stepwise logistic regression 
was performed to determine the most clinically significant variables in the 
regression model that were associated with a decision to terminate a pregnancy.  
The most important predictor was determined to be earlier offer of termination 
(23.041 ± 6.96 weeks of gestation vs. 25.625 ± 6.74 weeks of gestation; p = 
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0.027) (n = 113).  This corresponds to an odds ratio for termination of pregnancy 
of 0.93 (95 % CI, 0.87, 0.99) for each week of advancing gestational age. 
 
3.7 Patients’ decisions about termination of pregnancy after the 
detection of fetal abnormalities 
 
Termination of pregnancy was offered to approximately 69 % (117) of patients 
who had a fetal abnormality diagnosed.  Fifty percent (58) of the patients were 
offered TOP after 24 weeks gestation, while 45 % (52) were between 13 and 24 
weeks gestation, and only 4 % (5) were in less than 12 weeks gestation.  Of 
those patients who were offered TOP, approximately 62 % (73) elected to 
terminate the pregnancy (Table 3-6 and Figure 3-4).      
 
Table 3-6 Pregnancy outcomes of patients with diagnosed fetal abnormalities who received 
genetic counselling from the Division of Human Genetics, NHLS and WITS. 
Variable n % 
TOP offer   
No. of patients offered TOP 117 (68.8) 
No. of patients not offered TOP 53 (31.2) 
Total 170 (100.0) 
   
Gestational age at offer of TOP   
≤ 12 weeks 5 (4.4) 
13-24 weeks 52 (45.2) 
≥ 24 weeks
b
 58 (50.4) 
Total 115
a
 (100.0) 
   
TOP choice   
No. of patients who had TOP 73 (62.4) 
No. of patients who chose not to have TOP 44 (37.6) 
Total 117 (100.0) 
  a For two patients the gestation when TOP was offered was not known 
  b 24 weeks is considered the gestation of viability in South Africa 
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Figure 3-4 Percentage of individuals, who received genetic counselling from the Division of 
Human Genetics, NHLS and WITS, and who were offered termination of 
pregnancy.  The percentage of those who then chose to terminate the pregnancy 
is also shown. 
   
3.8 Genetic counselling service provided to patients with diagnosed 
fetal abnormalities  
 
The audit of the genetic counselling service offered to patients with diagnosed 
fetal abnormalities included determining the number of genetic counselling 
sessions the patient had during the pregnancy and whether they were followed-
up after TOP or delivery (Table 3-7).  If no follow-up appointment was made, the 
reason for this was determined from the records, if possible (Table 3-8).   
 
The majority of patients who received genetic counselling for a fetal abnormality 
had one session during the pregnancy (99, 59 %).  Patients who had more than 
one session tended to be those who chose to continue the pregnancy (Figure 3-
5).   
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Data were available regarding the follow-up service offered to 167 of the 171 
patients in the study.  In 4 cases it was unknown whether the patient opted for 
TOP or not because they were not followed-up or notes were not made in the file.  
A follow-up appointment for after TOP or delivery was not made in 104 (62 %) 
cases.  From Table 3-8, it can be seen that in 63 out of 104 (61 %) cases where 
no appointment was made, it was because no appointment was booked by the 
genetic counsellor involved (Figure 3-6).  Therefore, in total, 63 out of 167 (38 %) 
patients who should have had a follow-up appointment did not, because it was 
not booked by the genetic counsellor.  Significantly more patients were given 
follow-up appointments after TOP than after delivery after the continuation of the 
pregnancy.       
 
When a follow-up appointment was booked, the patients attended the session 
approximately 78 % (29) of the time (Figure 3-7).  Patients who chose to have 
TOP were seen for follow-up on average 57 days (approximately 8 weeks) after 
the last appointment in the pregnancy, while those patients who continued their 
pregnancies were seen on average 120 days (approximately 17 weeks) after the 
last appointment during the pregnancy.  There was a significant difference (p < 
0.01) in the interval between the last appointment in the pregnancy and the 
follow-up appointment between patients who chose to terminate affected 
pregnancies and patients who continued affected pregnancies.         
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Table 3-7 Genetic counselling service provided by the Division of Human Genetics, NHLS 
and WITS, to patients with diagnosed fetal abnormalities, comparing patients 
who chose to terminate their pregnancy and those who continued their 
pregnancy.  Patients who continued their pregnancy did so either by choice or 
because they were not offered termination of the pregnancy. 
Variable TOP Continue Combined p-value 
No. of genetic counselling sessions 
during the pregnancy  n % n % n %  
1 46 (63.0) 53 (56.4) 99 (59.3) 
2 17 (23.3) 29 (30.8) 46 (27.5) 
3+ 10 (13.7) 12 (12.8) 22 (13.2) 
Total 73 (100.0) 94 (100.0) 167 (100.0) 
0.587
a 
        
Follow-up appointment after TOP or delivery    
Follow-up appointment made 37 (50.7) 26 (27.7) 63 (37.7) 
Follow-up appointment not made 36 (49.3) 68 (72.3) 104 (62.3) 
Total 73 (100.0) 94 (100.0) 167 (100.0) 
0.004
a
** 
        
Follow-up appointment attendance     
Patient attended 29 (78.4) 20 (76.9) 49 (77.8) 
Patient did not attend 8 (21.6) 6 (23.1) 14 (22.2) 
Total 37 (100.0) 26 (100.0) 63 (100.0) 
1.000
a 
        
Interval between last appointment in 
pregnancy and follow-up 
appointment (days) (n = 55) 
56.8 ± 25.97 
119.55 ± 
118.23 
79.62 ± 
79.19 
0.004
b
** 
 a 2-tailed p-value determined through Fischer’s exact test 
b 2-tailed p-value determined through two-sample t-test with equal variance 
** Statistically significant at the 1 % level 
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Figure 3-5 Number of genetic counselling sessions provided by the Division of Human 
Genetics, NHLS and WITS, that patients had during the pregnancy in which a 
fetal abnormality had been diagnosed.  The percentage of patients who had 1, 2 
and 3 or more genetic counselling sessions is shown for those who chose TOP 
and for those who chose to continue their pregnancies, including all patients in 
the study. 
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Figure 3-6 Breakdown of the reasons why no follow-up appointment was made for after TOP 
or delivery for patients who received genetic counselling from the Division of 
Human Genetics, NHLS and WITS, after the diagnosis of a fetal abnormality. 
 
Table 3-8 Reason for no follow-up appointment being made for after TOP or delivery for 
patients who received genetic counselling from the Division of Human Genetics, 
NHLS and WITS, after the diagnosis of a fetal abnormality. 
Reason for no follow-up appointment TOP Continue Combined 
 n % n % n % 
No appointment made by GC
a 23 (63.9) 40 (58.8) 63 (60.6) 
Patient was to contact GC for appointment 4 (11.1) 11 (16.2) 15 (14.4) 
Patient did not want appointment 5 (13.9) 3 (4.4) 8 (7.7) 
Appointment not necessary 0 (0.0) 3 (4.4) 3 (2.9) 
Patient disappeared or could not be contacted 4 (11.1) 11 (16.2) 15 (14.4) 
Total 36 (100.00) 68 (100.00) 104 (100.00) 
a GC – genetic counsellor 
 
14% 
8% 
3%
14% 
61% 
No appointment made 
by GC 
Patient was to contact
GC for appointment 
Patient did not want 
appointment 
Appointment not
necessary 
Patient disappeared or 
could not be contacted 
 42 
23%
22%
77%
78%
0%
10%
20%
30%
40%
50%
60%
TOP Continue
Follow-up appointment made 
P
e
rc
e
n
ta
g
e
 o
f 
in
d
iv
id
u
a
ls
Pt did not attend F/U Pt attended F/U
 
Figure 3-7 Comparison of follow-up service offered by the Division of Human Genetics, 
NHLS and WITS, to patients who had TOP and those who continued their 
pregnancy after the detection of fetal abnormalities.  The breakdown of what 
percentage attended their follow-up appointment is also shown. 
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CHAPTER 4  DISCUSSION 
 
4.1 Introduction 
 
This research took the form of a retrospective audit of the genetic counselling 
files of patients who were seen for genetic counselling regarding diagnosed fetal 
abnormalities, in the Division of Human Genetics, NHLS and WITS, between 
2002 and 2006. 
 
This discussion will critically assess the results obtained during this research, 
following the format of the results.  Limitations that were noted during the course 
of the research and recommendations for future research are included. 
 
4.2 Patient numbers 
 
4.2.1 Number of patients seen for genetic counselling regarding a diagnosed 
fetal abnormality between 2002 and 2006 
 
A total of 171 patients were identified who had received genetic counselling for a 
diagnosed fetal abnormality by the Division of Human Genetics, NHLS and WITS 
between 2002 and 2006.  This represents only 1.1 % of pregnancies expected to 
be affected by prenatally detectable congenital disorders, in the Johannesburg 
area (See Section 3.2).  This may be explained by the fact that prenatal 
diagnosis and screening, as well as genetic counselling, are not accessible to all 
patients in Johannesburg, and therefore congenital disorders that would be 
detectable prenatally are not being detected.  Another difficulty in the state health 
care system is that patients may not be appropriately referred from primary 
health care clinics to facilities where prenatal screening, diagnosis and genetic 
counselling are available (Christianson et al., 2006; Watcham, Schon and 
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Christianson, 2007).  The genetic counselling service that is provided to couples 
who have had fetal abnormalities detected may have personal value for those 
who receive it, but the service has limited public healthcare value.    
 
4.2.2 Trend in patient numbers over time 
 
The number of patients seen for genetic counselling increased from 2002 until 
2004, as the genetic counselling service grew and more clinics were developed.  
However, there has been a large decrease in the number of patients seen since 
2004 (Figure 3-1), because one of the larger prenatal genetic counselling clinics 
stopped functioning in 2005.     
 
4.3 Patient information 
 
The majority of patients seen were Black (Table 3-1).  The high proportion of 
Black patients in this study (123, 72 %) is comparable to the population statistics 
of Gauteng, where 74 % of the population is Black (StatsSA, 2001).  Amongst the 
patients included in this study there was a high proportion of unemployment (72, 
42 %). This high unemployment rate is in keeping with the fact that our Genetic 
Counselling Clinics function predominantly in tertiary state hospitals in the 
Johannesburg area, Gauteng.  These hospitals mainly serve individuals who 
cannot afford private medical care and, therefore, a high proportion of 
unemployment would be expected in this sample group.   
 
The HIV status of patients seen for genetic counselling for a diagnosed fetal 
abnormality was unknown for the majority of patients (125, 73 %) (Table 3-1).  
This could be due to a number of reasons: HIV testing may not have been 
performed, the genetic counsellors may not have requested the information or 
they may not have noted it in the file.  Mseleku et al. (2005) reported that 
approximately 30 % of patients attending antenatal clinics at Johannesburg 
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Hospital were HIV positive.  Approximately 57 % of patients (26) in our study, 
whose HIV status was known, were HIV positive.  A possible explanation for this 
apparently increased prevalence is that genetic counsellors may be more likely to 
note when a patient is HIV positive, thus inflating the number of HIV positive 
patients relative to HIV negative patients.      
 
4.4 Fetal abnormalities diagnosed in patients seen for genetic 
counselling 
 
4.4.1 Initial reason for referral to genetic counselling 
 
The majority of patients in this study were initially referred because an 
abnormality was detected on ultrasound examination (140, 82 %) (Table 3-2).  
The rest of the patients were initially referred because of an increased risk of fetal 
abnormality, which was determined through screening.  Screening was done by 
asking about maternal age and family history, and ultrasound examination, 
including nuchal translucency measurement and the identification of soft 
markers.  Our data is in keeping with a study by Hassed et al. (1993), done in the 
United States of America, who reported that abnormalities detected on 
ultrasound was the most common indication for referral for genetic counselling, 
with positive serum screening tests the second major reason.  In our study, there 
were a low number of referrals to the genetic counselling service for positive 
serum screening tests, compared to Hassed et al. (1993), because serum 
screening tests are not available in the state hospital system in Gauteng, South 
Africa.   
 
4.4.2 Gestation at diagnosis of the fetal abnormalities and offer of TOP 
 
The mean gestation at diagnosis of fetal abnormalities was 23.3 ± 7.0 weeks with 
44 % (75) of fetal abnormalities being diagnosed after 24 weeks gestation.  Fifty 
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percent of patients (58) were only offered TOP after 24 weeks gestation (Table 3-
2).  This means that patients who wish to have TOP are often faced with having a 
fetocide due to the late gestation.   
 
The gestation at diagnosis and at offer of TOP is in keeping with that found in 
international studies.  A large study in 61 European obstetric units, found that 
only 44 % of fetal abnormalities were detected before 24 weeks, with diagnoses 
being made at 25.8 ± 7.5 weeks on average.  They reported that the gestation at 
diagnosis was dependent on whether there were single or multiple abnormalities, 
and the type of abnormality detected (Grandjean et al., 1999).     
 
There are a number of possible reasons for the offer of TOP being made so late 
in gestation in our clinics.  Firstly, patients are being referred from primary health 
care clinics late in pregnancy, thus resulting in late assessment at a tertiary 
hospital where prenatal screening and diagnosis are more readily available 
(Christianson et al., 2006).  In addition, many of the most frequently occurring 
abnormalities, such as hydrocephalus and skeletal abnormalities, are only 
evident at later gestations (Vaknin, Ben-Ami, Reish et al., 2006). 
 
4.4.3 Organ systems affected by the fetal abnormalities 
 
Intracranial CNS abnormalities (60, 35 %) were the most commonly detected 
abnormalities in our sample group, with cardiovascular abnormalities (46, 27 %) 
the second most common, followed by neck and face abnormalities (44, 26 %) 
(Table 3-2).  A study conducted in an urban South African hospital looked at the 
frequency of involvement of specific organ systems in live born babies with 
congenital disorders (Delport, Christianson, van den Berg et al., 1995). The top 
three organ systems affected by abnormalities in this study were the CNS, 
including intracranial abnormalities and NTDs, the musculoskeletal system, and 
the cardiovascular system.  Rauch et al. (2005) determined the frequency of 
involvement of specific organ systems when the abnormalities were detected 
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prenatally by fetal medicine specialists using ultrasound in the United States of 
America.  They found that the cardiovascular system was the most commonly 
affected, followed by the neck and face, and the gastrointestinal system (Table 4-
1).   
 
Table 4-1 Comparison of the three most frequently occurring abnormal organ systems in 
our study, another prenatal study and a group of babies born with congenital 
abnormalities 
Our research group Rauch et al., 2005
a 
Delport et al., 1995
b 
Organ system % Organ system % Organ system % 
Intracranial CNS 35 Cardiac 39 CNS (intracranial & NTD) 19 
Cardiac 27 Neck and face 32 Musculoskeletal 18 
Neck and face 26 Gastrointestinal 30 Cardiac 15 
a
 
Prenatal study 
b
 
Postnatal study 
 
Cardiac abnormalities were among the three most commonly detected 
abnormalities in all three studies shown in Table 4-1.  The high number of 
prenatally detected cardiac abnormalities suggests a high level of expertise of the 
professionals performing the ultrasound examination in our study.  This 
correlates with the fact that the majority of ultrasound examinations in this study 
were performed by fetal medicine specialists. 
 
Delport et al. (1995) found CNS abnormalities to be the most commonly affected 
organ system in live born babies.  Their study showed that 43 % of the reported 
CNS abnormalities were NTDs, while our study showed that only 14 % (10) of the 
CNS abnormalities were NTDs.  This difference in the proportion of intracranial 
abnormalities versus NTDs may be explained by the fact that less intracranial 
abnormalities are detected postnatally since cranial ultrasound examinations are 
not routinely done, and such abnormalities may only be suspected when 
developmental delay becomes evident.  In addition, the small sample number in 
this study may not accurately reflect the situation in the greater population.  
However, the proportion of NTDs, relative to abnormalities in other organ 
systems detected prenatally in our study (6 % of affected organ systems) was 
similar to Rauch et al. (2005) (11 % of affected organ systems).    
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Abnormalities of the neck and face were common in both this study and in the 
fetal abnormality study by Rauch et al. (2005).  In Delport et al.’s study (1995), 
abnormalities of the neck and face were included within other organ systems, 
and therefore cannot be compared to our data.  
 
Musculoskeletal abnormalities in our study only included skeletal abnormalities 
(40, 23 %), because muscle abnormalities are not detectable on ultrasound 
examination.  This may account for the lower prevalence of musculoskeletal 
abnormalities in our study and that of Rauch et al. (2005), compared to the 
postnatal study done by Delport et al. (1995).       
 
4.4.4 Diagnostic test results 
 
Of the 97 patients who had invasive diagnostic testing or STORCH investigation, 
45 % (44) had abnormal results (Table 3-2).  Down syndrome was the most 
common chromosome abnormality detected by invasive testing (14, 32 %), with 
Trisomy 18 the second most common (10, 23 %) (Table 3-2).  In a study of 
pregnant women attending the Antenatal Clinic at Groote Schuur Hospital, 
Viljoen, Oosthuizen and van der Westhuizen (1996) also reported that Down 
syndrome and Trisomy 18 were the most common chromosome abnormalities 
identified, each accounting for 32 % of the abnormalities.     
 
One might have expected Down syndrome to have been diagnosed at a much 
higher frequency than Trisomy 18 because it is a more common chromosome 
abnormality.  An explanation for the similar frequencies of Down syndrome and 
Trisomy 18 reported in these results may be that, when using second trimester 
ultrasound examination, Trisomy 18 has a prenatal detection rate of 64.9 % while 
Trisomy 21 has a prenatal detection rate of 26.7 % (Stoll et al., 2001).  Since 
second trimester ultrasonography was the main screening tool used for the 
patients in this study, it is likely that many fetuses with Down syndrome are 
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missed, while those with Trisomy 18 are detected.  This theory is supported by 
the fact that all the fetuses with Trisomy 18 diagnosed through invasive testing 
also had abnormalities detected on ultrasound, while only 5 out of the 13 fetuses 
(38.5 %) diagnosed with Down syndrome had abnormalities detected on 
ultrasound.  Half (7) of the patients who had Down syndrome diagnosed through 
invasive testing were initially referred for AMA counselling, suggesting that AMA 
screening may be beneficial in the absence of other screening modalities.  Only a 
small proportion of patients in this study presented early enough in the first 
trimester for nuchal translucency screening and maternal serum screening is not 
offered in the state hospitals.  Second trimester ultrasound examination for fetal 
anomalies at 18 – 23 weeks gestation is often the only screening tool for Down 
syndrome available to non-AMA patients.  As discussed, the detection rate of 
Down syndrome using ultrasound screening, without nuchal translucency 
screening, is low (26.7 %) in low-risk populations, resulting in many undetected 
cases (Stoll et al., 2001).  
 
4.5 Comparison of those patients who chose termination of 
pregnancy to those who chose to continue their pregnancy after 
the detection of a fetal abnormality 
 
Patients who chose termination and those who chose to continue their 
pregnancies after the detection of a fetal abnormality were compared in terms of 
their age, ethnicity, relationship status, parity, HIV status, gestation at diagnosis 
and offer of TOP, number of organ systems affected, CNS involvement, whether 
diagnostic testing was performed, and the result of diagnostic testing.  The most 
relevant variables are discussed.  
 
 50 
4.5.1 Ethnicity 
 
Ethnicity was the only variable when analysed independently that was 
significantly different between patients who chose to terminate and those who 
chose to continue an affected pregnancy.  Black patients chose TOP significantly 
less often than patients of other ethnic groups.   
 
Black patients may be more likely to continue affected pregnancies for religious 
reasons, although this was not addressed in this study and may be an important 
factor for future research.  A South African study comparing Muslim patients to 
patients of other religious groups found that religious belief was a significant 
factor in the decision about TOP (Viljoen et al., 1996). 
 
Similarly, Black patients may be more inclined to leave the outcome of their 
pregnancy to fate.  Kuppermann, Learman, Gates et al. (2006) reported that 
African-American women have higher levels of fatalism than women from other 
ethnic groups.  They also showed that higher scores on a fatalism scale were 
associated with lower willingness to terminate an affected pregnancy (Learman, 
Drey, Gates et al., 2005).    
 
We were unable to find any publications that looked at the reasons why Black 
South African women were less likely to terminate an affected pregnancy.  This is 
a potential area for future research. 
 
4.5.2 Maternal age, relationship status, and parity 
 
Schechtman et al. (2002) found that older patients are more likely to terminate an 
affected pregnancy.  However, in our study patients who terminated were on 
average younger, although this was only approaching statistical significance.  
Drugan et al. (1990), Pryde et al. (1992) and Rauch et al. (2005) showed no 
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impact of maternal age on the decision regarding TOP when abnormalities had 
been diagnosed.   
 
Christian et al. (2000) showed that there is no significant impact of parental age 
or relationship status on the decision patients make regarding the outcome of a 
pregnancy with a diagnosed sex chromosome abnormality.  The results of our 
study also show no influence of relationship status on the decision.  Parity was 
also not found to be a significant factor in the decision to terminate an affected 
pregnancy in this study.  This was also reported by Drugan et al. (1990), Pryde et 
al. (1992), and Rauch et al. (2005). 
 
4.5.3 Gestation at diagnosis of the fetal abnormalities 
 
The gestation at diagnosis of the fetal abnormality was not shown to be a 
significant indicator of the decision to TOP in this study.  The same was reported 
by Pryde et al. (1992), but is in contrast to the conclusions of Rauch et al. (2005), 
who found that when fetal abnormalities are diagnosed earlier patients are more 
likely to opt for termination.    
 
4.5.4 Gestation when TOP was offered 
 
The offer of termination of the pregnancy was typically made late in the second 
trimester or in the third trimester, although it was on average later for patients 
who chose to continue their pregnancy than for those who chose to terminate.  
This suggests that when termination was offered later, patients were more likely 
to continue the pregnancy, although this was only approaching statistical 
significance and so should be interpreted with caution.   
 
A possible reason for patients being less likely to terminate a pregnancy later in 
gestation is that the patient bonds more with the pregnancy as it progresses 
(Pryde et al., 1992; Drugan et al., 1990).  In some religions TOP is absolutely 
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forbidden, for other religious groups late TOP is unacceptable (Zlotogora, 2002).  
This could also explain why patients are more likely to terminate affected 
pregnancies when the offer is made earlier.  In addition, for some patients their 
moral and personal values and beliefs may make it unfavourable to choose 
termination at a later gestation.  In addition, as the pregnancy progresses the 
procedure required to terminate the pregnancy may become more complex, and 
thus may impact on women’s feelings and the decisions they make about TOP 
(Davies et al., 2005).  Women may be less likely to terminate when the procedure 
required is more complicated and risky.  
4.5.5 CNS involvement  
 
Schechtman et al. (2002) report that when there is CNS involvement, patients are 
more likely to terminate an affected pregnancy.  Our research showed that CNS 
involvement did not have a significant influence on the decision to terminate or 
continue an affected pregnancy.  This may be because of the smaller size of the 
study population in this research project.  
 
4.5.6 Diagnostic testing 
 
When comparing patients who had diagnostic testing and those who did not, 
there was no significant difference in the decision regarding termination of 
pregnancy.  There was also no significant difference between patients who had 
an abnormal diagnostic test result and those who had a normal diagnostic test 
result in terms of whether they chose TOP or continuation of the pregnancy.  This 
suggests that the possibility of having a defined diagnosis compared to a 
collection of abnormalities on ultrasound examination does not impact the 
decision patients make about the outcome of the pregnancy.  We could not find 
any literature that compared the decision about TOP made by patients who 
chose to have diagnostic testing and those who did not or the differences 
between patients with normal and abnormal results. 
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4.6 Factors found to have an impact on a patient’s choice regarding 
TOP for a detected fetal abnormality 
 
Variables that were identified through a stepwise logistic regression to have a 
significant or borderline significant impact on the decision to terminate or 
continue an affected pregnancy were manually modeled using logistic regression.  
Patients who were offered TOP at earlier gestations were found to be more likely 
to choose TOP than patients who were offered TOP later in their pregnancy.   
These results are in concordance with those of Rauch et al. (2005), who reported 
that earlier detection of fetal abnormalities was the most important factor 
associated with the decision to terminate an affected pregnancy.  
 
Possible reasons for why patients may be more likely to opt for TOP at earlier 
gestations has been discussed under the univariate analysis (Section 4.5.4).         
 
4.7 Decisions about termination of pregnancy 
 
Termination of the affected pregnancy was offered to approximately 69 % (117) 
of the patients who had fetal abnormalities detected.  Of those patients who were 
offered TOP, approximately 62 % (73) chose to terminate the pregnancy (Table 
3-6).  In a previous study, carried out in the Western Cape in South Africa, Viljoen 
et al. (1996) reported that 76 % of patients with a detected fetal abnormality 
opted for TOP.  Conversely, Rauch et al. (2005) reported a 33 % TOP 
acceptance rate after the detection of a fetal abnormality in the second trimester, 
in a study done in the United States of America.  It has been suggested that the 
characteristics of the fetal abnormalities detected and the population group of the 
patient have an influence on the decision patients make regarding TOP 
(Schechtman et al., 2002; Rauch et al., 2005).  The difference in acceptance 
rates between the three studies mentioned here may therefore reflect differences 
in the study groups in terms of the characteristics of the fetal abnormalities 
detected, as well as different population groups.     
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4.8 Genetic counselling service offered to patients with diagnosed 
fetal abnormalities 
 
Only 38 % (63) of patients with detected fetal abnormalities were seen for a 
follow-up genetic counselling appointment after termination or delivery (Table 3-
7).  The most common reasons for no follow-up appointment included no 
appointment being booked by the genetic counsellor (63, 61 %), the patient not 
contacting the genetic counsellor to make another appointment (15, 14 %) and 
the patient disappearing (15, 14 %) (Table 3-8).  Information about whether the 
fetus was examined after a termination was not recorded in this study, but it 
would be a recommended variable for future research as it represents another 
form of follow-up.   
 
Follow-up after the detection of a fetal abnormality is important for patients 
because it provides an opportunity for the results of any tests to be discussed 
and for the provision of psychosocial support.  Patients who choose to continue 
their pregnancy need to be seen so the baby can be examined and appropriately 
managed and a diagnosis potentially made (Weil, 2000).    
 
Patients who chose to terminate an affected pregnancy were more likely to have 
a follow-up appointment made than patients who continued the pregnancy to 
delivery.  This may be because the genetic counsellor focuses on the emotional 
needs of patients who choose to terminate.  It may also be because patients who 
choose termination are likely to deliver sooner than patients who choose to 
continue their pregnancy.  It is often not possible for the genetic counsellor to 
predict the exact delivery date or to know the outcome of a continued pregnancy, 
which makes it difficult to know when to schedule the follow-up appointment.  
Patients who choose to continue an affected pregnancy are often told to phone 
the genetic counsellor after the birth of the baby or that they will be contacted 
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after the birth to organise an appointment, however, this invariably does not 
happen due to the difficulties discussed below.       
 
In total, 38 % of patients did not have a follow-up appointment made because the 
genetic counsellor involved did not make the appointment.  This may occur 
because the genetic counsellor plans to wait until after the expected delivery date 
to contact the patient to make an appointment, but then forgets to do so.  It is 
possible that the counsellor does phone or make contact with the patient but 
forgets to make a note in the counselling file.  A recommendation may be to 
make the booking at the final appointment during the pregnancy, for 
approximately 6 weeks after termination or the expected date of delivery.  The 
appointment can be confirmed prior to the session, thus reducing the chance that 
the patient does not remember.   
 
When follow-up appointments are made, the patients attended the appointment 
in 78 % (49) of cases (Table 3-7).  This suggests that if the appointment is made, 
the patient is likely to come.  This suggests that patients value the service that is 
being offered.  This was true for both patients who chose to terminate and those 
who chose to continue their pregnancies.   
 
When follow-up appointments are made they are, on average, 80 days after the 
last appointment during the pregnancy.  When patients chose to terminate, the 
follow-up appointment occurred 57 days (~ 8 weeks) after the last appointment in 
the pregnancy (Table 3-7).  The recommended interval, used by our department 
(Division of Human Genetics, NHLS and WITS), between the last appointment 
during the pregnancy and the follow-up appointment for patients who choose 
termination is 6 weeks, thus 8 weeks is probably acceptable.  The interval for 
patients who chose to continue the pregnancy was, on average, 120 days (~ 17 
weeks) (Table 3-7).  It is difficult to judge the appropriateness of this interval, as 
the time between the last appointment in the pregnancy and the follow-up 
appointment after delivery depends on the gestation that the patient was seen at.  
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Some patients are seen early in the pregnancy, while others may be seen just 
before delivery.           
 
4.9 Limitations of this research 
 
From the beginning of this research project it was thought that notes in some of 
the counselling files may not be complete, and this could result in missing data.  
This was confirmed during the data collection phase of the research when 
information that was expected to be in the files was not found.  However, we do 
not think that the missing information had a large impact on our results. 
 
The sample population, although satisfactory for the scope of this research 
report, is not large enough to draw conclusions about the factors that may be 
associated with the decision to terminate a pregnancy affected by fetal 
abnormalities.  The inclusion of more patient files would allow generalisations to 
be made. 
 
4.10 Recommendations 
 
4.10.1 Recommendations for future research 
 
With respect to the specific variables that were recorded during the research, 
there are a number of additional variables that could have been recorded and 
analysed as they may be associated with the decision to terminate an affected 
pregnancy.  These include the severity of the detected abnormalities, the 
religious beliefs of the patients and their education level.  The inclusion of these 
variables in future work may provide more information regarding the decisions 
patients make regarding the outcome of affected pregnancies.  In addition, when 
recording whether patients had diagnostic testing or not, it would be useful to 
record which patients were offered diagnostic testing.  Patients who choose to 
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have diagnostic testing, specifically invasive testing, may be more likely to 
choose termination, than patients who decline diagnostic testing.   
 
When assessing the genetic counselling service offered to patients with detected 
fetal abnormalities it would be beneficial to record when a fetus was examined 
after a TOP, as this would allow follow-up to be more thoroughly assessed. 
 
4.10.2 Recommendations for improving the genetic counselling service offered 
 
Follow-up appointments should be made during the last appointment in the 
pregnancy, regardless of whether the patient has chosen to continue or terminate 
the pregnancy.  This will ensure that patients are adequately followed-up, and 
receive the necessary management and support. 
 
Efforts should be made to develop and expand the genetic counselling service 
offered so that the larger community has access to it. 
 
4.11 Conclusion 
 
The genetic counselling service provided by the Division of Human Genetics, 
NHLS and WITS, to patients with diagnosed fetal abnormalities is limited in its 
availability to the larger community.  The service may be valuable to the patients 
who have access to it, but it has limited public health care value.   
 
The gestation when fetal abnormalities are diagnosed, and thus when TOP is 
offered, is consistent with the timing of the fetal anomaly scan.  However, many 
fetal abnormalities could be detected earlier if ultrasound screening was initiated 
earlier in pregnancy.  This research suggests that earlier gestation at offer of 
TOP is the most clinically important predictor of the decision to terminate an 
affected pregnancy.  This supports the idea that the detection and diagnosis of 
fetal abnormalities as early in pregnancy as possible is beneficial for the patients 
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who are faced with the decision of whether to terminate or continue an affected 
pregnancy.    
 
Two thirds of the patients who were offered termination of the affected pregnancy 
chose to undergo TOP.  This reflects the importance of giving patients the choice 
to terminate a pregnancy when fetal abnormalities are detected. 
 
The genetic counselling follow-up service that is offered by the Division of Human 
Genetics, NHLS and WITS, needs to be improved.  Patients do not receive 
adequate follow-up, particularly those patients who choose to continue the 
pregnancy.  This means that many babies with abnormalities that are known to 
the division are born and not assessed again.  The fact that patients who do 
receive follow-up appointments generally attend the appointment indicates that 
the service is valued and wanted by the patients.  Follow-up appointments should 
be booked at the last appointment during the pregnancy, and confirmed shortly 
before the appointment. 
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APPENDIX A: ETHICS CLEARANCE CERTIFICATE 
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APPENDIX B: GENETIC COUNSELLING INFORMATION 
SHEET 
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APPENDIX C: DATA COLLECTION SHEET 
SUBJECT CODE:                              . 
 
 
Biomedical Information: 
 
 
1. Maternal date of birth:                                                    . 
 
 
2. Maternal age at diagnosis of the fetal abnormality:                                             . 
   
 
3. Ethnicity:    
1. White  2. Black        
3. Indian  4. Mixed Ancestry    
5. Other   6. Unknown     
 
 
4. Relationship status:  
1. Single    2. Divorced/Separated             
3. Widowed     4. Married     
5. In a relationship   6. Unknown    
 
 
5. Employment status:     
     1. Employed         2. Unemployed           
3. Self-employed       4. Unknown          
 
 Occupation:    . 
 
 
Pregnancy History: 
 
 
6. Gravidity: 
1   2   3    4  5   6   7   8   9    10  
 
 
7. Parity: 
1   2   3    4  5   6   7   8   9    10  
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8. Number of fetuses in the pregnancy: 
1   2   3     
 
 
9. Gestational age by sonar at the time of the diagnosis of the fetal abnormalities: 
      . 
 
 
10. Total number of fetal abnormalities detected: 
1   2   3    4  5   6   7   8   9    10  
 
 
11. Fetal abnormalities detected:  
                                                        .    
 
 
12. Number of soft markers identified on sonar: 
1   2   3    4  5   6   7   8   9    10  
  
 
13. Soft markers detected:                                                         .    
 
 
14. Fetal abnormalities detected in the following organ system(s): 
 1. Cardiovascular   2. Pulmonary       
3. Neurological  4. Skeletal   
5. Gastrointestinal    6. Genitourinary  
  7. Neck and face  8. Other   
          . 
 
 
15. The abnormality was considered lethal: 
 1. Yes   2. No  
 
 
16. The prognosis of the fetal abnormality was certain: 
 1. Yes   2. No  
 
 
17. Diagnostic procedures performed: 
 1. Ultrasound scan    2. Amniocentesis    
 3. Cordocentesis       4. Chorionic villus sampling  
 5. STORCH screen  
 
 
18. Result of diagnostic procedure:                                                         . 
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19. Was the patient referred to specialist doctors: 
 1.Yes   2. No  
 
 
20. If yes, to what specialist doctors was the patient referred:                                .
  
 
 
21. Whether termination of pregnancy was offered: 
 1.Yes   2. No  
 
 
22. What gestational age was termination of pregnancy offered:  .  
 
 
23. Was the pregnancy terminated: 
 1.Yes   2. No  
 
24. Number of genetic counselling consultations during the pregnancy: 
1   2   3    4  5   
  
 
25. Was a follow-up appointment made for after TOP or delivery: 
 1.Yes   2. No  
 
 
26. Did the patient attend the follow-up appointment: 
 1.Yes   2. No   3. Not applicable  
 
 
27. Interval between the last appointment in the pregnancy and the follow-up                   
 appointment after TOP and delivery:     . 
 
28. Reason for no follow-up appointment being made: 
1. No appointment made by GC     
 2. Patient was to contact GC for appointment   
 3. Patient did not want appointment    
 4. Was to be referred again if necessary    
 5. Appointment not necessary     
 6. Patient disappeared or could not be contacted  
 
 
 
29. Initial indication for genetic counselling: 
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 1. Abnormality on ultrasound        
 2. AMA        
 3. Family History       
 4. Positive screening test      
 5. Teratogen        
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